What is he best known for?
The fields of study he is best known for:
Angiogenesis, Cancer research, Vascular endothelial growth factor, Cell biology and Pathology are his primary areas of study.
His Angiogenesis research is multidisciplinary, incorporating elements of Vascular endothelial growth inhibitor, Cancer, Endocrinology and Immunology.
Rolf A. Brekken interconnects Tumor progression, Extracellular matrix and Metastasis in the investigation of issues within Cancer research.
His Vascular endothelial growth factor research includes themes of Endothelium and HIF1A.
His Cell biology research incorporates elements of Matrix metalloproteinase and Cell growth.
His research investigates the connection between Pathology and topics such as Adenocarcinoma that intersect with problems in Molecular imaging, Microbubbles, Gemcitabine, Endoglin and Stromal cell.
His most cited work include:
- Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2287 citations)
- Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue (563 citations)
- SPARC, a matricellular protein: at the crossroads of cell-matrix communication. (451 citations)
What are the main themes of his work throughout his whole career to date?
Rolf A. Brekken focuses on Cancer research, Cancer, Pancreatic cancer, Angiogenesis and Metastasis.
His biological study spans a wide range of topics, including Cancer cell, Tumor progression and Immune system, Immunology.
His research in Cancer focuses on subjects like Pathology, which are connected to In vivo.
The concepts of his Pancreatic cancer study are interwoven with issues in Gemcitabine, Cell, Oncology and Stromal cell.
His Angiogenesis study integrates concerns from other disciplines, such as Breast cancer, Signal transduction, Cell biology and Vascular endothelial growth factor.
When carried out as part of a general Metastasis research project, his work on Primary tumor is frequently linked to work in Osteonectin, therefore connecting diverse disciplines of study.
He most often published in these fields:
- Cancer research (60.78%)
- Cancer (23.28%)
- Pancreatic cancer (23.28%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (60.78%)
- Pancreatic cancer (23.28%)
- Immune system (11.76%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Cancer research, Pancreatic cancer, Immune system, Cancer and Cell.
His Cancer research research focuses on Tumor microenvironment in particular.
He has researched Pancreatic cancer in several fields, including Carcinoma, Regeneration, Hepatic stellate cell and Pancreas regeneration.
His studies in Immune system integrate themes in fields like Extracellular matrix and Cell type.
His research in Cancer intersects with topics in Flow cytometry, Personalized medicine and Ceritinib.
His Immunotherapy research incorporates themes from Triple-negative breast cancer, Angiogenesis and Chemotherapy.
Between 2018 and 2021, his most popular works were:
- Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. (48 citations)
- Pancreatic cancer stroma: an update on therapeutic targeting strategies. (44 citations)
- Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer (39 citations)
In his most recent research, the most cited papers focused on:
Rolf A. Brekken focuses on Cancer research, Pancreatic cancer, Immune system, Cancer cell and Cancer.
His Cancer research research integrates issues from Stroma, Carcinoma and Metastasis.
The concepts of his Metastasis study are interwoven with issues in Vascular endothelial growth factor, KRAS, Combination therapy, FOXP3 and Effector.
His work carried out in the field of Immune system brings together such families of science as Autophagy, Gemcitabine/cisplatin, Extracellular matrix and Chemotherapy.
His research in Cancer cell intersects with topics in Gene silencing, Cell signaling, MAPK/ERK pathway and AXL receptor tyrosine kinase.
Rolf A. Brekken focuses mostly in the field of Cancer, narrowing it down to matters related to Cell and, in some cases, Tumor progression, Phenotype, Proteomics and Carcinogenesis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
